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Background: India and the EU are currently negotiating a Trade and Investment Agreement which also covers
services. This paper examines the opportunities for and constraints to India-EU relations in health services in the
context of this agreement, focusing on the EU as a market for India’s health services exports and collaboration. The
paper provides an overview of key features of health services in the EU and India and their bearing on bilateral
relations in this sector.
Methods: Twenty six semi-structured, in-person, and telephonic interviews were conducted in 2007-2008 in four
Indian cities. The respondents included management and practitioners in a variety of healthcare establishments,
health sector representatives in Indian industry associations, health sector officials in the Indian government, and
official representatives of selected EU countries and the European Commission based in New Delhi. Secondary
sources were used to supplement and corroborate these findings.
Results: The interviews revealed that India-EU relations in health services are currently very limited. However,
several opportunity segments exist, namely: (i) Telemedicine; (ii) Clinical trials and research in India for EU-based
pharmaceutical companies; (iii) Medical transcriptions and back office support; (iv) Medical value travel; and (v)
Collaborative ventures in medical education, research, training, staff deployment, and product development.
However, various factors constrain India’s exports to the EU. These include data protection regulations; recognition
requirements; insurance portability restrictions; discriminatory conditions; and cultural, social, and perception-related
barriers. The interviews also revealed several constraints in the Indian health care sector, including disparity in
domestic standards and training, absence of clear guidelines and procedures, and inadequate infrastructure.
Conclusions: The paper concludes that although there are several promising areas for India-EU relations in health
services, it will be difficult to realize these opportunities given the pre-dominance of public healthcare delivery in
the EU and sensitivities associated with commercializing healthcare. Hence, a gradual approach based on pilot
initiatives and selective collaboration would be advisable initially, which could be expanded once there is
demonstrated evidence on outcomes. Overall, the paper makes a contribution to the social science and health
literature by adding to the limited primary evidence base on globalization and health, especially from a
developing-developed country and regional perspective.
Background
Health services have become increasingly globalized.
They are traded through all four modes of services
delivery as defined under the General Agreement on
Trade Services (GATS). Cross-border supply of health-
care takes the form of electronic delivery of healthcare
across countries (GATS mode 1); consumption abroad
takes the form of medical value travel (GATS mode 2);
foreign commercial presence takes place through invest-
ments in the healthcare sector (GATS mode 3); and
cross border movement of service providers involves the
circulation of doctors and nurses among countries
(GATS mode 4) The borderline between GATS modes
may, however, not always be clear or separable (as in
the case of electronic transactions involving modes 1
and 2) and all market segments may not be covered
under the GATS. Globalization of health services has
been facilitated by advancements in information and
communication technology, liberalization of foreign
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and service providers, and demographic dynamics. As a
result, today, health services are a subject of discussion
in multilateral services negotiations.
The health sector has also come under focus in bilat-
eral and regional trade and cooperation agreements. One
such prospective accord is the India-European Union
(EU) Trade and Investment Agreement (TIA) currently
under negotiation. The latter is India’s first agreement
with a major developed country bloc and extends beyond
goods into services, investment, and several other issues.
This agreement could potentially facilitate India’sg r o w -
ing bilateral trade and investment relations with the EU
in services, including health services.
This paper examines the opportunities for and con-
straints to India-EU relations in health services. It identi-
fies the various segments where there are opportunities
for India to export health services to the EU and to colla-
borate with the EU. It also identifies numerous regulatory
and other constraints which impede the development of
this bilateral relationship. The discussion is largely based
on in-depth discussions with a variety of stakeholders in
India’s health sector and official representatives from a few
EU countries, corroborated by secondary evidence. In
doing so, the paper makes a useful contribution to the
social science and health literature by not only adding to
the very limited information base available at present on
globalization and health, based on primary evidence, but
also by providing a North-South cum regional perspective.
The paper has two main conclusions. The first is that
although India and the EU have very different health sys-
tems in terms of public-private composition, regulatory
frameworks, and policy priorities, several factors make
this sector conducive to expanding bilateral commercial
relations and collaboration between the two. The EU
member countries with their ageing populations, rising
costs, and overburdened public healthcare systems could
benefit from expanded relations with a country like India
with its growing private healthcare sector, emergence of
world class corporate hospitals, large pool of medical
manpower, and young population across a variety of seg-
ments. The second conclusion is that given the nature of
many of the constraints currently affecting this bilateral
relationship and given the public good nature of health
services, it would be best to take a gradual approach to
expanding bilateral engagement in this sector, building
on collaborative efforts selectively and over time moving
towards more commercial engagements.
Overview of the EU’s Health Services Sector: implications
for bilateral relations
Healthcare is a vital and strategic sector in the EU. On
average, the EU spends close to 8 percent of its GDP on
health [1]. Total healthcare spending in the EU-27
amounted to US $1.2 trillion in 2005, with France,
Germany, and the UK constituting the three largest mar-
kets. The public sector dominates healthcare delivery.
Public spending constituted 77 percent of total health-
care expenditures in 2005 for the EU-27 and close to 90
percent in certain EU countries [2]. The large volume of
healthcare spending is indicative of this sector’ss t r a t e g i c
economic and social importance for the EU, which is
likely to influence bilateral relations with other countries
in this sector. The dominance of public spending in
healthcare suggests that any bilateral discussions would
be influenced by public sector concerns. In this regard, it
is worth noting that although the EU has undertaken
ambitious commitments on hospital services in its 1993/
94 GATS schedule, it has reduced the coverage of these
commitments under its Economic Partnership Agree-
ment with the CARIFORUM to “privately funded ser-
vices”, reflecting the sensitivity surrounding commitment
of publicly funded services in a trade agreement. State-
ments by the European Services Forum (ESF), which
represents the interests of private sector services entities
in the EU, similarly reflect the recognition of health and
education services as special sectors where government
plays an important role and that public health services
must not be challenged by trade negotiations. According
to the ESF, countries should be free to determine if they
wish to open up their health services sectors to foreign
providers.
The EU Member States provide universal or near-uni-
versal public coverage for health as part of a wider sys-
tem of ‘social protection’.T h i si se x t e n d e dt oh e a l t h
services that are prescribed by health professionals or
institutions registered with the health insurance system
or which figure on the country’s positive list of approved
procedures, drugs, and medical devices. Private insur-
ance offering ‘supplementary’ cover accounts for a small
part of total healthcare financing, extending to services
such as dental or alternative treatment which are not
covered by the statutory systems, and providing supple-
mentary coverage for elective treatments. The domi-
nance of public insurance coverage has an important
bearing on prospects for bilateral relations with non-
member countries through modes such as medical value
travel. It implies that issues of insurance coverage and
portability are likely to be important and that the scope
for medical value travel would be shaped by the effi-
ciency and availability of health care under public health
systems in the EU, and limited to areas where patients
spend out-of-pocket or have limited insurance coverage.
Within the EU, nationals can elect to get treated in
another member country for pre-approved procedures
or in cases of undue delay, if they carry a European
Health Insurance Card (EHIC), also called the EU Medi-
cal Card. The latter entitles its holders to receive
Chanda Globalization and Health 2011, 7:1
http://www.globalizationandhealth.com/content/7/1/1
Page 2 of 13treatment at reduced cost when visiting European Eco-
nomic Area (EEA) countries and authorizes reimburse-
ment by the patient’s home country. It is important to
note though that although the European Health Card
facilitates treatment within the EU, it is subject to
restrictions. It does not entail treatment on the same
terms as those provided in the patient’s home country
and instead provides for treatment on the same terms as
that provided to nationals of the host country. It also
does not cover treatment for conditions existing before
travel or treatment by private providers and few coun-
tries pay the full cost of treatment and travel insurance
still remains necessary.
There is also an initiative to standardize health cards
across member countries by providing an interoperable
format that would help a patient prove entitlement to
healthcare from different national health services or to
medical insurance schemes in Member States. Such fra-
meworks have implications for medical value travel pro-
spects with non-EU countries versus EU member
countries. Issues of level playing field between members
and non-members are likely to feature in the EU’s
health services negotiations.
Another important aspect of the EU’s healthcare sys-
tem is the role of IT in healthcare delivery. The e-health
industry in the EU was estimated at US $27.7 billion in
2006. Europe could potentially account for one-third of
the global health ICT industry of US $66-79 billion [3].
Although the extent of IT integration in healthcare
delivery varies across EU member countries, there is a
general push in this direction due to ageing populations,
rising operational costs, and the need to improve service
access and quality. Several member countries have
launched e-health initiatives. The adoption of IT in
healthcare has implications for cross-border delivery of
healthcare services to EU member countries, from
within the region and outside, in areas such as telera-
diology, telediagnostics, medical coding, transcriptions,
and back-office support functions.
The EU market for e-health, however, remains frag-
mented with differences among member countries in
their approach to IT adoption. There are also concerns
about patient privacy, liability, and consumer safety, as
reflected in very stringent data protection directives and
regulations, at the EU and national levels [4]. The EU’s
Privacy Rule establishes regulations for the use and dis-
closure of Protected Health Information (PHI), which
refers to any information about health status, provision
of healthcare, or payment for healthcare that can be
linked to an individual. The EU’s General Directive on
Data Protection is based on the principles of legitimacy,
finality, transparency, proportionality, confidentiality and
security, and control. This is supplemented by a Security
Rule which deals specifically with Electronic Protected
Health Information (EPHI) and specifies three types of
security safeguards required for administrative, physical,
and technical compliance, with security standards and
specifications for each standard [5].
One important aspect of the EU’s data protection
directive pertains to data transfers to non-member
countries [6,7]. It requires that Member States enact
laws that prohibit transfer of personal data to countries
outside the EU which fail to ensure adequate privacy
protection. The Data Protection Commissions and
Member States are required to inform each other in
such cases. The data adequacy determination require-
ment and concerns over issues of data privacy and con-
sumer protection have implications for cross-border
electronic delivery of health services to the EU by non-
member countries such as India and raise issues of level
playing field vis-à-vis member countries.
Regulations concerning standards and eligibility
requirements for healthcare providers in the EU are also
likely to affect bilateral relations in health services with
non member countries. There are requirements pertain-
ing to registration, language certification, and insurance
coverage, as well as compliance requirements with EU-
wide as well as national-level legislation in areas such as
telemedicine, clinical trials and research activities.
Health professionals are regulated at the level of Mem-
ber States and, to some extent, at the EU level [8].
There are two broad regimes for recognition of qualifi-
cations in the EU: (a) the sectoral system, based on
common minimum training standards defined in rele-
vant sectoral directives which lead to automatic recogni-
tion of the diploma; and (b) the “general system”,w h i c h
may require a case-by-case evaluation of the diploma by
national authorities with the option to impose compen-
sation measures [9]. Dentists, medical doctors, midwives,
nurses, pharmacists and veterinarians are covered by the
sectoral system; all other health professionals are cov-
ered by the general system [10]. These recognition
requirements include competence assessment, certifica-
tion requirements, specification of minimum training,
and other conditions for the medical profession. Such
regulations are likely to influence the ability of profes-
sionals and establishments to supply health services to
the EU from outside the region as well as the portability
o fr e c o g n i t i o nw i t h i nt h eE Ug i v e nc o u n t r y - s p e c i f i c
requirements [11].
Another important issue which is pertinent to the
EU’s bilateral relations with non-member countries is
the exclusion of health services from the scope of the
EU services directive. Notwithstanding initiatives to pro-
mote cross-border cooperation and to harmonize inter-
nal systems in healthcare among member countries, the
latter retain their national legislation and regulatory fra-
meworks to address concerns of consumer safety,
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to have a single services market in the health sector
reflects the wide variety in funding and delivery
mechanisms that individual EU member states apply in
their health care sectors and the extent to which compe-
tition between suppliers and insurers is admitted. This
has implications for the extent to which the EU can be
considered as a single bloc by third countries which
wish to export to this region and also the extent to
which the European Commission is in a position to
negotiate on behalf of the entire Union. The non-applic-
ability of the services directive to health care reflects a
deeper problem of incompatibility among member
states. Hence, negotiations in this sector are likely to be
difficult and a selective engagement with a few markets
within the EU may be more likely.
There are numerous challenges facing the EU’s health-
care sector which have a bearing on its bilateral rela-
tions with countries like India. In a comprehensive
report, the European Observatory on Health pointed out
several issues facing the region’s healthcare systems,
including ageing populations and pressures on health-
care spending, limited human resources, the need to
modernize and redesign national health services and
improve management of the healthcare system, rising
costs and unsustainable public health expenditures, long
waiting times, and the need to give patients greater
choice [12]. Such challenges potentially justify engage-
ment through trade and collaborative arrangements
within and outside the EU to alleviate these constraints.
For example, long waiting times have resulted in
increased pressure from patients in several EU countries
to access services across borders. Sickness funds in
some EU countries have contracted hospitals across
borders to alleviate this pressure. In addition, there is
demand for unauthorized and non-contracted care in
other EU countries. In recent years, some EU countries
have initiated reforms by undertaking quality assurance
programs, providing guarantees of reduced local waiting
times, facilitating intra-EU patient mobility and e-health,
and initiating efforts to expand their health workforce,
but the problems still persist. Hence, there are opportu-
nities for providers in non-EU countries through
outsourcing, medical value travel, movement of health
personnel, and educational and research partnerships,
which could potentially alleviate these cost and accessi-
bility pressures. Regional agreements and collaboration
could be used to facilitate such ties.
Overview of India’s health services sector: implications for
bilateral relations
The Indian healthcare delivery market was estimated at
US $34 billion and employed over four million people
in 2008, making it one of the largest service sectors in
the economy today. Total national healthcare spending
stood at 4.1 percent of GDP in 2007 and is projected to
double to 8 percent of GDP or $77 billion by 2012. The
industry has grown at about 13 per cent annually in
recent years and is expected to grow at 23 percent per
year over the next few years [13]. Growth has been
mainly driven by rising incomes, growing propensities to
spend on healthcare, shift to lifestyle-related diseases,
and demographic factors.
The sector comprises many segments. Estimates and
projections for the individual segments show promising
trends in several segments such as clinical trials, diag-
nostics, hospitals, medical devices, and health imaging.
Nevertheless, India’s healthcare sector falls well below
international benchmarks for physical infrastructure,
manpower, and existing standards in comparable devel-
oping countries. It is estimated that investment of $78
billion is required in health infrastructure and an addi-
tional 800,000 physicians are required over the next 10
years [14]. Considerable scaling up is required in the
availability and quality of physical infrastructure and
human resources.
One of the most important aspects of India’s health-
care system is the significant role of the private sector,
which accounts for over 75 percent of India’st o t a l
healthcare spending. Private players account for 75 per-
cent of dispensaries, 80 percent of all qualified doctors,
and an estimated 95 percent of new hospital beds in
recent years. Public health expenditure accounts for less
than 1 per cent of GDP. Government spending on
healthcare infrastructure (excluding land) is projected to
rise only marginally, by 0.12 per cent of GDP and the
private sector is expected to provide 88 per cent of
investment requirements over the medium term [15].
However, private healthcare delivery is highly fragmen-
ted with over 90 per cent of it being serviced by the
unorganized sector according to a recent report, and
suffers from huge variation in quality and standards
[16]. The growing dominance of private providers is sig-
nificant for India’s bilateral engagement with the EU. It
suggests that the discussions are likely to be and are
already being led on the Indian side by the private sec-
tor directly through industry consultations and delega-
tion visits to these markets as well as being channelled
through the government, while the counterparts in the
EU are the governments and national health authorities.
The latter in turn suggests potential conflicts of interests
and concerns given the public-private nature of these
discussions.
The regulatory environment in India’s healthcare sec-
tor also has a bearing on its relations with other coun-
tries. Regulations in several areas pertinent to trade
relations, such as standards for medical establishments,
accreditation of medical professionals, and foreign direct
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being introduced for medical establishments, such as the
recently introduced accreditation program for secondary
and tertiary hospitals by the National Accreditation
Board for Hospitals & Healthcare Providers (NABH) to
improve the quality of healthcare establishments in the
country, and which has also received international
recognition by ISQua (International Society for Quality
in Health Care). Similar standards have been prescribed
for Indian laboratories by the National Accreditation
Board for Laboratories to ensure compulsory registra-
tion of all clinical establishments and compliance with
prescribed minimum standards, periodic inspections and
inquiries, and cancellation of registration or penalties if
conditions are not met. These recent efforts to establish
regulatory frameworks and better governance mechan-
isms for healthcare providers are significant as they have
a bearing on India’s prospective discussions with other
countries on issues of mutual recognition of standards
and insurance portability.
Certification of medical professionals is another
important issue that has a bearing on cross-border rela-
tions. Although India has established regulations at the
central and state levels for medicine, dentistry, and nur-
sing with rules for registration, practice, and enforce-
ment of standards, there remain shortcomings. National
level regulatory bodies and norms are lacking in areas
such as paramedical services, standards and training
tend to be non-uniform across educational establish-
ments within the country, and there are no mutual
recognition agreements with developed countries for
qualifications of healthcare professionals. Such issues are
likely to feature importantly in any efforts to develop
bilateral relations with the EU in healthcare.
The globalization of India’s healthcare sector in recent
years has significance for India’s cross-border engage-
ments in health services, including with the EU. Rapid
growth as well as the emergence of international quality
private players in India’s healthcare sector has created
opportunities for trade, investment, and collaboration,
cutting across all four GATS modes of delivery. Accord-
ing to secondary sources and discussions with industry
experts, there are many existing and prospective oppor-
tunity segments for India to trade health services. With
regard to mode 1, India has prospects in many aspects
of e-health, including teleradiology, telediagnostics, tele-
pathology, intensive care (or remote monitoring via tele-
ICU), ophthalmology (remote diagnosis of eye pro-
blems), dermatology (remote diagnosis of skin pro-
blems), tele-psychiatry (using videoconferencing, TV
cameras, and microphones to connect patients and psy-
chiatrists for diagnosis, assessment, medication manage-
ment and second opinions) and continuous online
remote monitoring. These prospects are driven by
India’s cost advantage and the quality of its radiologists
and specialized technical staff. Telehealth in these areas
provides a means to address the shortage of physicians
in the respective segments in the importing countries.
Independent telemedicine providers, reputed hospitals,
and large Indian IT companies are currently providing
telemedicine services to the US, Singapore, and several
South and Central Asian countries. India is also an
attractive market for healthcare business process out-
sourcing. Some reputed hospitals are partnering with
US companies for billing, documentation of clinical and
administrative records, coding of medical processes, and
insurance claims processing services. Outsourcing of
pathology services to India is another emerging opportu-
nity area for Indian diagnostic labs.
India also has promising prospects in the area of med-
ical value travel (mode 2). The medical value travel mar-
ket in India was estimated at $333 million in 2004 and
is projected to reach $2.2 billion by 2012 [17]. These
prospects are driven by India’s cost advantage, availabil-
ity of world-class hospitals, and push factors in client
markets. The cost of comparable treatment in India is
on average one-eighth to one-fifth of those in the West
and compares favourably with costs in other medical
value travel destinations such as Thailand [18]. How-
ever, these exports remain constrained by lack of insur-
ance portability and lack of accreditation of Indian
healthcare providers by overseas health insurance trusts
and private insurance companies.
Other segments where India is seeing growing oppor-
tunities are medical devices and clinical research and
trials (in part facilitated by investments by overseas
companies in India’s health services and health products
market). Many foreign companies are entering the
Indian market through joint ventures and tie-ups in
medical devices production and testing, training, and
research. Some foreign companies conduct the first sur-
geries in India after the approval of a medical device or
surgical treatment by their home authorities. The clini-
cal research and trials segment has grown significantly
with projected revenues of $1-2 billion by 2010 [19].
Some Indian research labs and Contract Research Orga-
nizations (CROs) provide sophisticated tests like mole-
cular diagnostics for autoimmune disorders, cytogenetics
and diseases related to abnormalities and also conduct
bioequivalence studies. Some laboratories offer a wide
menu of tests under one roof to foreign companies.
Leading healthcare providers have received approval
from overseas authorities to conduct clinical trials,
including fast-track clinical trials.
India is also an established exporter of healthcare work-
ers including doctors, nurses, and technicians (mode 4).
Although much of this movement has been in the form of
permanent migration, there are growing prospects for
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tutional tie-ups with overseas establishments, to leverage
India’s cost advantage and manpower availability and also
address the pressures of ageing populations and shortage
of healthcare workers in developed countries. Non-unifor-
mity of domestic standards of medical training, lack of
mutual recognition, and immigration restrictions, how-
ever, constrain such prospects at present.
Methods
T h e r ei sl i t t l eo rn oe v i d e n c eo nt h ec u r r e n ts t a t u so f
trade and investment flows between India and specific
partner countries or regions such as the EU. The aca-
demic literature on bilateral relations in health care
between India and specific countries is very limited,
mostly consisting of industry and consulting firm
reports with focus on specific segments.
This study relies on primary research, supplemented
by secondary sources to understand the nature and
extent of relations between India and the EU in health
services. The primary survey consisted of 26 semi-struc-
tured interviews of a variety of stakeholders, including
Indian health services firms, practitioners, government
officials, and industry experts over the 2007-2008 per-
iod. The interviews were conducted in person and over
the phone. The cities of Bangalore, Delhi, Kolkata, and
Mumbai where major health service providers are
located were covered.
The sample of healthcare establishments included lead-
ing Indian hospitals, telemedicine firms, clinical and spe-
cialized research firms, business process outsourcing firms
in healthcare management, and medical equipment and
technology firms. The practitioners covered include doc-
tors, researchers, radiologists, biotechnologists, and senior
management at health services firms. The segments and
stakeholders were selected based on initial discussions
with industry experts, other academics, and reading of sec-
ondary literature which helped identify both existing and
prospective areas for India’s trade in health services, not
only with the EU but more generally. The interviews then
specifically addressed the opportunities and challenges
with respect to the EU. The aim of these discussions was
to understand the range of services currently being pro-
vided by Indian providers to EU-based clients, the oppor-
tunities realized or perceived by them in the EU market,
and the main barriers to doing business with the EU,
including how the EU compared as a trading partner in
this sector vies-a-vies other countries.
In order to validate these findings and to get alternate
perspectives, views were also solicited from representa-
tives in Indian industry associations, economic counsel-
lors of the German and French embassies and the
European Commission, and experts at the British High
Commission based in New Delhi, and a UK-based
medico-legal expert. Semi-structured and customized
discussion guides were used for all interviews. The find-
ings were presented at stakeholder consultations orga-
nized in New Delhi and Bangalore in February 2008 and
2009, respectively, and were strongly validated by parti-
cipants. Further insights were also obtained at these
consultations and incorporated.
Secondary research was used to gather background
information on health services in India and the EU to
understand key characteristics of this sector and their
bearing on trade, investment, and collaboration opportu-
nities between the two, as outlined in the preceding
background section, and to corroborate the interview
findings. Several health and economic databases (OECD
and Eurostat) were also searched. Secondary information
on India was primarily obtained from reports by indus-
try associations, international agencies, researchers, con-
sulting firms, and the popular media. The literature
search focused on the post 2000 period.
Results
This section provides an overview of the interview find-
ings on the prospects and challenges concerning India-
EU relations in health services and the general factors
likely to shape this relationship.
Overview of opportunities and constraints in the EU
The interviews indicated that bilateral commercial and
other relations in this sector are very limited at present,
also corroborated by the absence of data and studies in
this regard. However, they also indicated several nascent
and promising opportunity segments where bilateral
engagement in the health sector could be developed.
These were:
1. Telemedicine, most importantly teleradiology fol-
lowed by telediagnostics, telpathology, bioinfor-
matics, and continual remote monitoring;
2. Clinical trials and research in India for EU-based
pharmaceutical companies and CROs;
3. Medical transcriptions, revenue cycle manage-
ment, and other back-office support functions;
4. Medical value travel, especially for elective and
out-of-pocket expenditures and alternative therapies
and treatments;
5. Collaborative ventures between universities, hospi-
tals, and research centres on medical education,
research, training, staff deployment (especially
nurses) and exchange, and product development
under establishment-establishment arrangements
and intergovernmental agreements
Broadly, two issues emerged regarding opportunities.
First, respondents were generally more optimistic about
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those with minimal patient contact and interface, i.e.,
the telemedicine, clinical trials and research, and back-
office segments. Views were mixed regarding prospects
in segments such as medical value travel or medical
staffing as these were seen as directly subject to public
perception and political, social, cultural factors that
would be difficult to overcome in the EU.
Second, the discussion revealed that markets of inter-
est to Indian healthcare providers vary within the EU
depending on the opportunity segment in question. In
telemedicine, the UK’s National Health Service (NHS)
was identified as the main client market for telemedicine
exports from India while in the clinical trials and
research segment, Germany and the Scandinavian coun-
tries were seen as important prospective markets due to
their pharmaceutical base, inclination towards research
and development, and acknowledgment of Indian exper-
tise. In the area of personnel staffing and exchange, the
UK (particularly the NHS) was identified as the main
market, though potential was also perceived in the
English language-inclined countries of Scandinavia, Ger-
many, and the Netherlands. In medical value travel,
apart from the UK, countries such as Germany, France,
and the Scandinavian countries were seen as potential
source markets given their inclination towards rehabili-
tative and alternative treatments and tourist interest in
India. In general, the UK was seen as the main market
for language and culture-dependent areas and emerged
as the main market within the EU across almost all
opportunity segments.
The interviews also revealed a variety of constraints
faced by Indian healthcare providers in providing health
services to the EU market. These pertained to regulation
in EU Member States or at the EU-wide level, which
included: (1) restrictions on outsourcing certain kinds of
health services to providers outside the EU territory;
(2) data protection and data exclusivity laws; (3) accredi-
tation and certification requirements for healthcare
establishments and compliance issues with international
or EU standards and guidelines; (4) insurance portability
restrictions and coverage issues; (5) recognition of
professional qualifications and registration requirements;
(6) immigration and visa regulations affecting mobility
of providers; and (7) national treatment restrictions and
discriminatory treatment which put Indian healthcare
p r o v i d e r so na nu n e v e np l a y i n gf i e l dw i t hE U - b a s e d
providers and undermined their market access vis-à-vis
competitor countries in the EU.
However, respondents made a distinction between
constraints and barriers, clearly accepting that some
regulations and requirements are warranted on public
policy grounds such as protecting consumers, ensuring
patient safety, and maintaining standards. In their view,
it is often the associated administrative processes in the
EU that create impediments as they are very cumber-
some and time consuming, with approvals required
from multiple institutions and regulatory authorities,
and compliance requirements at the EU and country
levels. The findings also highlighted the significance of
social, linguistic, cultural, and perception-related factors
in shaping the prospects for India-EU relations in health
services, given the human resource-intensive and custo-
mer-service oriented nature of healthcare delivery. Both
Indian and foreign respondents further highlighted regu-
latory, institutional, and infrastructural factors in India
as constraining India’s exports of health services to the
EU market and the world market at large.
Broadly, two general factors emerged as key to shap-
ing India-EU relations in health services. The first was
awareness. Most Indian respondents noted that Indian
healthcare providers have limited understanding about
the healthcare sector in most EU countries excepting
the UK’s NHS. Since each EU country has its own com-
plex and evolved healthcare system, according to the
respondents, this lack of awareness within the Indian
health provider community automatically constrains the
scope for providing healthcare services to the EU market
at large. Likewise, Indian respondents also pointed out
that apart from the UK, there is limited awareness in
the EU about the quality and capabilities of Indian
health services providers.
The second factor that emerged as critical for shaping
bilateral relations in health care was linguistic, social,
and cultural affinity. Lack of such affinity between India
and most EU countries was seen as a major constraint
to India’s delivery of healthcare and related services to
the EU market. Respondents noted that healthcare is a
highly personalized service where perceptions, attitudes,
and social and linguistic ties play an important role.
Thus, India’s prospects were perceived to be limited to
the UK market and a few EU countries that have Eng-
lish-speaking capabilities.
Discussion
This section provides a detailed discussion of the survey
findings for each of the identified opportunity segments.
It highlights the existing status and prospects for bilat-
eral engagement in each segment and associated con-
straints in the EU and in India.
Prospects in Telemedicine
The interviews with Indian and EU respondents high-
lighted telemedicine, especially tele-radiology as one of
the most promising areas for expanding bilateral rela-
tions, the key driver being the shortage of qualified per-
sons and the launching of e-health initiatives in several
EU countries. At present Indian firms do not provide
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deem India to be a data secure country. Hence, they do
not permit outsourcing of patient data to India for tele-
medicine purposes. But discussions with management
and practitioners at two leading Indian telemedicine
establishments revealed that these data protection
restrictions are expected to be removed eventually by
the EU authorities once there is greater awareness of
Indian providers and their capabilities and the cost
advantages of outsourcing telemedicine become evident.
This view was corroborated by secondary sources which
indicated that several Trade Commissions from EU
member countries have in recent years shown interest
in outsourcing telemedicine work to India.
The interviews further revealed that some Indian
firms are taking a long-term perspective and are adopt-
ing different strategies to circumvent these restrictions,
for example, by establishing subsidiaries and partner-
ships within the EU in order to serve the EU market
from within. Such commercial presence enables them to
bid for teleradiology contracts that are being outsourced
by some EU governments as their European subsidiaries
are not subject to outsourcing restrictions on patient
data. One leading Indian teleradiology firm confirmed
that it has incorporated a subsidiary in the EU to
undertake such work from within the EU and is also
investing in a dedicated section at its India office to
cater to prospective clients in the EU and gain a first-
mover advantage in that market. Another leading Indian
telemedicine provider has similarly used its overseas
presence in the UK to tap the emerging business in tel-
emedicine. It has a subcontract from a private consor-
tium that has obtained a NHS contract for radiology
reporting within the UK. The Indian firm has set up a
local office in the UK staffed by Indian radiologists who
are sent from India on a rotational basis to do the
reporting work.
However, Indian providers noted four major con-
straints to providing telemedicine services for the EU,
namely, data protection regulations, lack of recognition
of the qualifications of Indian providers, contractual
issues, and perceptions regarding India as a healthcare
provider. The key aspects of these barriers and how they
affect telemedicine exports from India to the EU are
summarized in Table 1.
Prospects in clinical research and trials
This segment, though nascent, was seen to be very pro-
mising for expanding commercial relations and colla-
boration between India and the EU. Some Indian
companies are conducting clinical trials for European
pharmaceutical companies. Some Indian CROs have set
up marketing offices in a few EU countries, while others
are acquiring companies in the EU and elsewhere to
build their image and credibility. Although secondary
data were not readily available to estimate the magni-
tude of this business with the EU, experts who were
interviewed estimated that Indian companies were doing
only some $100 million worth of clinical trials work for
the EU compared to around $3 billion of work being
done by the Eastern European countries.
However, as in the case of telemedicine, the interviews
revealed that Indian companies are taking a long term
view of the European market and plan to expand their
business in the EU. Some Indian CROs are holding dis-
cussions with companies in the UK, Germany, and Italy.
There has also been interest by Swedish, Danish, Ger-
man, and Finnish companies about conducting clinical
research and trials in India for faster turnaround. Some
areas of interest for European companies are Phase I
and II studies on diabetes, oncology, neuropsychiatry,
gastroenterology, and stem cell research. Respondents
also noted that there are ongoing discussions with Eur-
opean biopharma companies for proof of concept for
new drugs. European countries with the strongest phar-
maceutical sectors, namely the UK and Germany, were
seen as the most important markets in the EU. Indian
firms also noted the scope for research in experimental
therapies that could be conducted by Indian companies
or research centres in collaboration with European insti-
tutions and universities and for potential partnerships
between Indian and EU laboratories to get international
certification for evaluation and testing.
According to respondents, the driving force for
expanding India-EU relations in the clinical trials and
research segment would be the high drug development
costs, the limited patient pool, and slow recruitment
rate of patients for clinical trials in the EU. It was noted
that India is cost-effective for conducting clinical trials
given its huge population, diverse genetic pool, wide
range of diseases, drug-naïve population, trained medical
and technical manpower, and good hospitals for under-
taking such trials. According to these respondents,
Indian CROs can help EU-based pharmaceutical compa-
nies lower their costs and the time to market drugs.
Several constraints were also highlighted, though these
were often seen as necessary regulations and not bar-
riers per se. These constraints mostly pertained to data
exclusivity requirements, accreditation and certification
requirements for laboratories and organizations con-
ducting the trials, and contractual obligations. The inter-
views also revealed perception-related barriers due to
the lack of awareness in the EU about India’s capability
as a destination for clinical trials and research. There
were also concerns expressed by EU officials on ethical
grounds. Table 2 summarizes the main constraints that
emerged with regard to clinical trials and research, and
their resulting implications for Indian companies.
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To date, India’s medical value travel exports are mostly
to developing countries in South Asia, Africa, and the
Middle East. Interviews with practitioners and manage-
ment at leading Indian hospitals indicated that there are
very few medical value travellers from the EU to India.
The latter are limited to out-of-pocket patients and elec-
tive treatments. However, respondents were optimistic
about the prospects for expanding medical value travel
from several EU countries, especially the UK, given the
latter’s colonial, linguistic, and social ties with India.
This view was corroborated by secondary sources where
according to a survey conducted by the Treatment
Abroad website in 2007, over 70,000 British citizens
who travelled abroad for medical treatment noted India
as a destination of choice [20].
Table 1 Barriers affecting India’s Telemedicine Exports to the EU
Constraint Features and Implications
Data protection, privacy, and information
security issues [21]
￿ Bureaucratic EU data protection laws
￿ Cumbersome database registration requirement with data protection authorities
￿ Data on EU patients cannot be sent outside the EU unless legal basis for transfer, i.e., official adequacy
finding to determine country has national laws to provide adequate level of data protection
￿ India has not received adequacy determination from EU authorities, so needs to legalize data transfer
￿ Lack of harmonization in data protection legislation among members creates additional compliance
costs of security audits, fines, registration in signing contracts with clients in different EU member
countries
￿ Stringent national level legislations on data and information security and data privacy relating to
disclosure and use of Protected Health Information create additional administrative, physical, technical,
and organizational compliance costs (e.g., need to adopt information security standards along the lines
of the British Standard for Information Security management, BS-7799)
￿ Firms may need to set up commercial presence in EU and provide telemedicine from within EU to
overcome the absence of data adequacy determination for Indian providers based in India
Recognition and accreditation
requirements
￿ Very expensive and time-consuming (as long as one year per provider) certification process
￿ Multiple levels of verification with various professional bodies
￿ Stringent certification requirements for teleradiology companies and providers
￿ Registration required with each country’s healthcare commission and concerned authorities
￿ Compliance with EU directives on data protection, consumer safety, etc.
￿ Indemnity/insurance requirement
￿ Cumbersome evaluation and documentation requirements
￿ Competence determination tests
￿ Language requirements
￿ Residency requirements
￿ Requirement to appear in person for registration
￿ Recertification, revalidation, re-licensure, regular appraisal requirements
￿ Lack of harmonization within EU
￿ Implicit discrimination against non-EU providers
Contractual issues ￿ Practical problems with malpractice insurance and liability policies in EU countries
￿ Handling of breach of contract and jurisdictional issues in enforcing compliance
￿ Costs imposed due to service line agreement clauses on prior consent, indemnity, non-disclosure,
liability
￿ Delays in executing contracts
Perception, attitudes, and stakeholder
resistance
￿ Resistance to electronic delivery of healthcare in EU
￿ Cultural and social barriers
￿ Linguistic barriers, translation requirements for reports
￿ Resistance from professional associations in EU due to concerns over employment losses
Source: Based on interviews.
Table 2 Constraints affecting clinical trials and research
Problem Features and Implications
Standards and Accreditation ￿ Requirement to conform with client country guidelines often cumbersome
￿ Accreditation of Indian labs required even if they conform to accepted global standards
￿ Compliance costs of meeting documentation, audit, infrastructure, qualification, training requirements
Norms for clinical trials ￿ Stringent requirements for informed consent, transparency, adherence to prescribed norms
Data Protection ￿ India not perceived as data-secure
￿ Data exclusivity contracts have to be signed
￿ Detailed audits required
￿ Costs of litigation
Manpower mobility ￿ Problems in getting visas for technical persons sent by Indian CROs to clients in EU– short duration, single entry
Source: Based on interviews.
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tain countries of Eastern Europe, such as Poland, which
face challenges in their healthcare system following their
transition from socialism. They pointed to possibilities
in the form of commercial presence by Indian hospitals
or tie-ups with institutions in these countries, given the
latter’s need for affordable healthcare, lack of quality
medical infrastructure, exodus of medical personnel to
Western Europe following accession, and possible affi-
nity to India due to good political relations in the past.
However, the general view was that developing and
least developed countries rather than developed regions
such as the EU would continue to be the main sources
for medical value travellers to India. There was also gen-
erally much greater optimism among all respondents
about the prospects in alternative medicine and thera-
pies given growing interest in the West for treatment of
chronic disorders where allopathy fails to deliver.
Respondents noted that India has the potential to pro-
vide various streams of alternative medicine, including
panchkarma, ayurveda, unani, siddha, and homeopathy.
This finding was corroborated by rough estimates pro-
vided by some respondents on the share of European
patients seeking treatment at traditional allopathic ver-
sus alternative treatment facilities. The share of Eur-
opean patients at alternative treatment facilities was
over 50 percent in some cases while in all the traditional
corporate hospitals that were covered by this survey, this
share was less than 10 percent.
The in-depth discussions also pointed out various fac-
tors which limit and will probably continue to limit med-
ical value travel from the EU to India. These related to:
(i) Restrictions on reimbursement of patients from
the EU if travel to the exporting country exceeds a
certain duration, effectively affecting India’s attrac-
tiveness as a medical destination;
(ii) The relatively low share of non-insured and out-
of-pocket paying patients in the EU that automati-
cally limits the pool of patients who would opt for
treatment in India;
(iii) Dominance of the public sector as a provider of
insurance which creates problems of political accept-
ability in allowing medical value travel to India and
getting reimbursed by the national health insurance
trusts in EU countries;
(iv) Lack of accreditation of Indian hospitals and the
lack of recognition of Indian medical qualifications
which affect the scope for reimbursement for treat-
ment in India.
In addition, respondents noted the role of linguistic,
cultural, and social differences in limiting India’sm e d i -
cal value travel exports to the EU. They also stressed
the importance of perception given the fact that medical
value travel involves a close interface between the doc-
tor and the patient. In their view, attitudinal factors and
India’s lack of credibility as a medical value travel desti-
nation is likely to remain a constraint to such exports to
the EU. Table 3 summarizes the main constraints to
expanding medical value travel from the EU to India.
Prospects for back-office support services
One interesting opportunity segment that emerged from
the in-depth discussions was back-office business pro-
cess and support services in healthcare delivery and
administration. The interviews highlighted the existence
of such exports by Indian firms for the US market and
similar prospects for doing high-end, back-office work
in healthcare for the EU market.
One specific activity that was cited was revenue cycle
management, which involves taking patient bills and
records for processing reimbursements from insurance
companies. Respondents noted that such services involve
specialized expertise and that Germany has recently
expressed an interest in outsourcing medical transcrip-
tion as well as other IT-enabled services to India to over-
come its high costs and labour shortages in healthcare.
Another activity where Indian firms could provide spe-
cialized business process support services was medical
coding and analysis of patient charts to ease reimburse-
ment-related analysis by insurance companies. The inter-
views highlighted the prospects for providing such
coding services to the EU for data analysis and diagnostic
purposes, based on the European Procedural Terminol-
ogy. However, the discussions also highlighted several
constraints to India’s exports of back office health sup-
port services to the EU, several of them common to
Table 3 Constraints to India’s Medical Value Travel
Exports to the EU
Problem Features and Implications
Insurance portability
regulations
￿ State insurance trusts and private insurance
companies do not accept treatment in India for
reimbursement
￿ Flight time restrictions for UK patients (limited
to 3 hours) for reimbursement from NHS
￿ Restrictions on reimbursement of alternative
medicines and therapies for lack of scientific
evidence and registration
Growing competition ￿ India at disadvantage relative to Eastern
European countries on qualification, e-health
delivery, movement of persons, insurance
portability
Perceptions ￿ Nationally sensitive issue, resistance to medical
value travel by national health providers
￿ Cultural, social, linguistic perceptions about
India
￿ Perceptions about India as a suitable
destination for medical value travel
Source: Based on interviews.
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implications are summarized in Table 4.
Prospects for collaboration in training, research, and
staffing
The interviews also indicated several areas for India-EU
collaboration in health services. Given the shortage of
personnel in several EU countries, respondents noted
that India could export medical personnel on a tempor-
ary basis to staff the national health systems of those
countries, particularly for nursing and paramedical ser-
vices. The UK was cited as the most important prospec-
tive market for deployment of health personnel.
Another potential area for collaboration, highlighted
by the interviews was medical education and training.
While the EU countries have thus far shown little inter-
est in entering India’s medical education segment, both
Indian and EU respondents noted that there are possibi-
lities for collaboration through technical tie-ups, dual
degrees, and twinning programs, which could be com-
bined with a period of deployment and practical training
in the EU following coursework. Indian respondents also
highlighted the fact that since the EU has excellent hos-
pitals with trained personnel and established processes
in subspecialty care, collaboration in post-graduate
training would help raise Indian standards while also
addressing labour shortages in those countries. Danish
authorities have expressed interest in such collaboration.
EU companies engaged in the development and produc-
tion of medical equipment and devices could potentially
be part of this collaboration by partnering with aca-
demic institutions and healthcare providers in India for
research and development and training services.
The interviews also indicated possibilities for colla-
boration in knowledge process outsourcing of specia-
lized and technical services for the healthcare industry,
such as design and production of medical devices and
testing of medical equipment. Companies such as Sie-
mens and Philips in India for the design, production,
and testing of medical equipment, as a global delivery
centre, and as a market for such products. According to
the respondents, the entry of large multinationals into
India in the medical devices segment as well as the
emergence of world class corporate hospitals in India
where such tests can be carried out are likely to drive
these outsourcing possibilities. In this regard, the pre-
sence of bilateral investment treaties (BITS) between
India and several EU member states (UK, France, Ger-
many, Austria, Belgium, Denmark, Italy, Sweden,
Poland, and Spain) could have a bearing on foreign
direct investment and research and development related
collaborations in the health care sector.
But collaboration was once again seen to be con-
strained by various factors. Linguistic differences and
lack of mutual recognition constrain possibilities for
staff exchange and deployment. Ethical regulations, liabi-
lity and compensation-related concerns, and lack of
international standards for registration of medical
devices and technologies in India affect the scope for
development and testing services for medical equipment
and devices. There was also a general view that the EU
has not been open to collaboration with India in the
healthcare sector. Table 5 highlights constraints affect-
ing specific areas where there are India-EU collaboration
prospects.
Constraints in India
The primary research also revealed the presence of
domestic constraints in India, which affect its exports of
health services to the EU and also other developed
country markets. These pertained to the lack of domes-
tic regulatory frameworks or lack of enforcement of
necessary regulations in India’s health sector, particu-
larly with regard to standards and accreditation of estab-
lishments and health personnel. Table 6 summarizes the
main constraints within India that were highlighted by
the interviews.
Table 4 Constrains to India’s provision of support
services in healthcare to the EU
Problem Features and Implications
Accreditation ￿ Certification required by concerned
regulatory bodies in various
segments (medical coding, analysis)
￿ Additional requirements of
continuing certification and
evaluation
Data privacy and restrictions on
international data transfer
￿ India is not empanelled as a data-
secure by EU authorities
￿ Restricts scope for data transfer and
related outsourcing
￿ Compliance costs of meeting EU
and individual countries’ data
protection legislation
Limited scope of the EU ￿ Resistance to outsourcing of back-
office functions in the EU
Source: Based on interviews.
Table 5 Constraints to collaboration in healthcare
between India and the EU
Problem Features and Implications
Political and social
sensitivities
￿ Affect staffing and temporary movement of
health personnel from India to EU countries
Recognition of
qualifications
￿ Qualifications and experience of Indian health
personnel not recognized in EU member
countries
￿ Re-certification and registration requirements
impose additional costs on Indian doctors
Other regulatory
issues
￿ Regulatory differences between India and the
EU on ethics, liability, and production and testing
Source: Based on interviews.
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to adopt a variety of regulatory measures and to align
its own standards and regulations to international ones.
This would enable India to leverage its capabilities in
health services for exporting to and entering into colla-
borative arrangements with EU member countries as
well as other developed regions.
Conclusions
Certain broad policy directions emerge from the find-
ings of this survey. Given the exclusion of health ser-
vices from the EU’s services directive, this is a
challenging sector to discuss in any trade agreement
with the EU. Moreover, given the sensitivities associated
with commercialization of health care, and the likely dif-
ficulties in addressing issues such as recognition, data
protection, or public attitudes in the EU in the short
term, a cross-cutting approach based on cooperation
might be more appropriate. Such collaboration would
need to be on a selective basis, between selected institu-
tions on both sides, between India and specific countries
in the EU, and in selected opportunity segments.
India-EU cooperation in healthcare could involve
institutional tie-ups, exchange of faculty, students, and
trainees, research collaboration, cooperation on
standards and recognition issues, and launching of joint
programs and pilot projects between India and EU
countries. Some specific areas for joint initiatives could
include:
￿ Institutional tie-ups to facilitate telemedicine and
medical value travel
￿ Partnerships and affiliations among labs and
research centres to facilitate work in the area of clin-
ical trials, and global recognition and certification of
Indian labs
￿ Reciprocal health agreements with selected markets
in the EU, along the lines of the agreements some of
these countries have with non-member nations for
treatments required during visits on emergency
grounds
￿ Provisions to facilitate partnerships and collabora-
tion among medical education and research institu-
tions in India and the EU
￿ Pilot programs for staff deployment and exchange
or medical value travel between select institutions
on both sides, supported by collaborative programs
in education, research, and training between selected
Table 6 Domestic Constraints to India’s Health Services Exports to the EU
Constraint Features and Implications
Accreditation and
standards
￿ Absence of mutual recognition agreements with key markets, requiring Indian providers to undergo cumbersome
certification and registration processes
￿ Lack of recognition prevents Indian companies from drawing on overseas pool of medical manpower
￿ Lack of standardization in medical and nursing training in India
￿ No regulatory body in some areas (paramedics)
￿ Authentication systems not perceived to be credible
￿ Lack of international accreditation by most Indian healthcare establishments, preventing medical value travel, insurance
portability, clinical trials outsourcing
￿ Lack of registration, standardization and overseas recognition of alternative medicines and therapies
￿ Lack of central laboratory accreditation that is recognized internationally (CAP)
Legal and regulatory
framework
￿ Bureaucracy and delays in approval process for clinical trials
￿ Delays in clearance for drug and sample shipments for testing
￿ Multiple clearances required by CROs for undertaking clinical trials (from multiple Ministries)
￿ Ethics approval process cumbersome as multiple committees involved
￿ Absence of legislation in certain areas (movement of drugs within India, lack of procedural controls on use of medical
devices)
￿ Poor enforcement of registration for clinical trials
￿ Slow regulatory clearances for bioequivalence studies
￿ Lack of clarity in guidelines for biotechnology products
￿ Jurisdictional issues about dispute resolution as lack of credible and efficient legal system in India
￿ Gaps between India’s clinical trials legislation and that of EU countries (e.g., requirement for pharmaceutical person for
issuing drugs in the EU, not in India)
￿ Concerns over violation of ethics by Indian CROs
Data protection ￿ Concerns over possible breach of data confidentiality after data submission to Indian regulatory body
￿ Lack of strict firewalls for data leakage, guidelines on data exclusivity lacking, not strictly enforced
Insurance and litigation ￿ Lack of insurance portability, public or private from EU (related to lack of recognition of Indian qualifications and
establishments)
￿ Malpractice liability issues: concerns over dispute resolution, jurisdiction, appropriate compensation
￿ Absence of insurance in India in emerging areas: clinical trials requiring insurance abroad at high cost
Other ￿ VAT and service tax charged on services of consultants monitoring clinical trials and reporting to client (export-oriented
services usually exempt from service tax)
￿ Delays in getting multiple entry visas for consultants monitoring clinical trials, short duration visas typical
￿ Delays in bringing certain medical devices into India affecting medical device testing, research-related outsourcing
Source: Based on interviews.
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India and the EU
￿ Tie-ups between Indian hospitals/research centres
and EU companies such as Siemens and Philips that
develop medical devices and equipment, for com-
mercial and academic reasons, also enabling Indian
companies, research centres, and labs to partner in
the engineering and design services work for the
development of medical equipment
Over time, the demonstrated outcomes of such
arrangements could provide the basis for expanding the
bilateral relationship to include more providers and
more EU member countries, and to cover more com-
mercially-oriented opportunities. Collaboration could
also help address longer term goals such as mutual
recognition and changing public perceptions in the EU.
For example, twinning programs, educational partner-
ships, and affiliations between institutions on both sides
could help provide the basis for future discussions on
equivalence of qualifications and mutual recognition.
Likewise, tie-ups in the area of telemedicine could pro-
vide the basis for discussing the removal of outsourcing
restrictions on patient data.
In parallel, the discussions would also need to focus
on streamlining administrative procedures in the EU
which act as impediments to Indian healthcare providers
and to address specific issues such as data adequacy
determination for India by EU data protection authori-
ties. Attention would also be required on domestic mea-
sures concerning standards and data protection for
India to effectively exploit its potential in health services
exports, not only to the EU but more generally. It
would also be important to link India’s potential as an
exporter of health services to its potential as a consumer
of health care, such as for medical devices, drugs, diag-
nostic equipment, and as a market for foreign invest-
ment by EU companies and hence the win-win
possibilities. Greater awareness would also need to be
created on both sides about the competencies in each
other’s markets.
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